Mainstay Medical International plc (Mainstay or the Company, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”), announces that Chief Executive Officer, Peter Crosby, and Chief Financial Officer, Hugh Kavanagh, will attend the Actionaria tradeshow in Palais des Congrès in Paris on Friday 18 and Saturday 19 November 2016.
Mainstay Medical will be pleased to welcome you to its booth B6 located on the second level of the Palais des Congrès to introduce the ReActiv8 system and detail the Company’s recent progress including: obtaining CE Marking for ReActiv8, triggering the start of European commercialization activities; completion of a private placement of €30 million; and the implant of the first subject in the ReActiv8-B Clinical Trial. The purpose of the ReActiv8-B Clinical Trial is to gather data in support of an application for pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA), a key step towards commercialization of ReActiv8 in the U.S.
If you would like to meet with Mainstay management at this event, please contact email@example.com
- End -
About the Actionaria tradeshow
Actionaria is a tradeshow to allow investors meet companies: a leading and unique tradeshow in Europe dedicated to individual investors. More than a hundred companies (large capitalisations, small & mid capitalisations, start-ups) will attend the tradeshow and over 30,000 visitors are expected. Individual investors will be able to meet the senior management of these companies.
Mainstay is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).
About Chronic Low Back Pain
One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.
People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry and governments.
Further information can be found at www.mainstay-medical.com
CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only
PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys
+44 203 709 5700 / +44 7921 697 654
FTI Consulting (for Ireland)
+353 1 663 3686
NewCap (for France)
+33 1 44 71 20 40
LifeSci Advisors, LLC
+1 (212) 915-2578
Fergal Meegan or Barry Murphy
+353 1 679 6363
firstname.lastname@example.org or email@example.com